Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly lawsuit could preserve $3.3bn of Sanofi revenues

This article was originally published in Scrip

Executive Summary

The mere act of filing a lawsuit against Lilly appears to have boosted Sanofi's top-line prospects to the tune of several billion dollars. The firm, which has made a tactical play that should hold a biosimilar version of its top-selling product off the US market for an extra 16 months even if it eventually loses the patent battle, could make an extra $3.3bn in sales for the four years from 2015 to 2018, according to the revised forecast from Goldman Sachs.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC024294

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel